兴银研究精选股票A（008537）成立日期2020年7月29日，最新规模4472.5万。今年以来收益24.07%， 同类排名2354/4220；近一年收益54.23%，同类排名1673/3824；成立以来收益8.1%。 9月26日，华恒生物涨5.17%，截至发稿，报34.60元/股，成交1.81亿元，换手率2.15%，总市值86.54亿 元。 资料显示，安徽华恒生物科技股份有限公司位于安徽省合肥市高新区长安路197号，成立日期2005年4月 13日，上市日期2021年4月22日，公司主营业务涉及氨基酸及其衍生物产品研发、生产、销售。主营业 务收入构成为：氨基酸系列70.96%，其他(补充)20.96%，维生素系列5.34%，其他产品2.74%。 从基金十大重仓股角度 数据显示，兴银基金旗下1只基金重仓华恒生物。兴银研究精选股票A（008537）二季度持有股数4.11万 股，占基金净值比例为2.42%，位居第七大重仓股。根据测算，今日浮盈赚取约6.99万元。 责任编辑：小浪快报 兴银研究精选股票A（008537）基金经理为乔华国。 截至发稿，乔华国累计任职时间1年323天，现任基金资产总规模1.18亿元，任职期 ...

Core Insights - The report highlights the significant increase in CFO salaries within A-share listed companies, with a total compensation of 4.27 billion yuan and an average salary of 814,800 yuan for 2024 [1][2] - Despite a 74.42% decline in stock price, CFO Fan Yi of Huaheng Biological saw a salary increase of 48.18%, raising concerns about the disconnect between executive compensation and company performance [1][2] Summary by Sections CFO Salary Overview - The total salary for CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average salary of 814,800 yuan [1] - Huaheng Biological's CFO, Fan Yi, received a salary of 1.62 million yuan, an increase of 526,700 yuan or 48.18% from the previous year [1][3] Company Performance - Huaheng Biological reported a total revenue increase of 12.37% to 2.178 billion yuan, but its net profit dropped by 57.80% to 190 million yuan [1] - The company's stock price fell by 74.42%, indicating a poor market performance despite revenue growth [1][2] Executive Background - Fan Yi has been with Huaheng Biological since January 2016, holding multiple roles including CFO and board secretary, and has prior experience in finance and mergers at BASF Greater China [2]